Novo Nordisk recently halted two Ziltivekimab heart trials, following a Phase 3 failure in July. This widens the market split to 60.9% for Lilly versus Novo's 38.8% in U.S. obesity/diabetes. Watch for Novo's 2025 outlook for sales decline implications.